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Abstract
Background: Misfolding, oligomerization, and fibrillization of a-synuclein are thought to be central events in the onset and
progression of Parkinson’s disease (PD) and related disorders. Although fibrillar a-synuclein is a major component of Lewy
bodies (LBs), recent data implicate prefibrillar, oligomeric intermediates as the toxic species. However, to date, oligomeric
species have not been identified in living cells.
Methodology/Principal Findings: Here we used bimolecular fluorescence complementation (BiFC) to directly visualize a-
synuclein oligomerization in living cells, allowing us to study the initial events leading to a-synuclein oligomerization, the
precursor to aggregate formation. This novel assay provides us with a tool with which to investigate how manipulations
affecting a-synuclein aggregation affect the process over time. Stabilization of a-synuclein oligomers via BiFC results in
increased cytotoxicity, which can be rescued by Hsp70 in a process that reduces the formation of a-synuclein oligomers.
Introduction of PD-associated mutations in a-synuclein did not affect oligomer formation but the biochemical properties of
the mutant a-synuclein oligomers differ from those of wild type a-synuclein.
Conclusions/Significance: This novel application of the BiFC assay to the study of the molecular basis of neurodegenerative
disorders enabled the direct visualization of a-synuclein oligomeric species in living cells and its modulation by Hsp70,
constituting a novel important tool in the search for therapeutics for synucleinopathies.
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Introduction
The deposition of cytoplasmic protein inclusions is a common
pathological feature of several neurodegenerative disorders. In
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB),
the main component of the inclusions is a-synuclein (aSyn), a small
neuronal protein of unknown structure and function [1].
Mutations in the gene encoding aSyn have also been linked to
familial cases of PD, suggesting a central role for this protein in the
etiology of both sporadic and familial cases of PD [2–5]. In vitro,
aSyn aggregation appears to be a nucleation-dependent process
where a variety of intermediate species, ranging from monomers
to fibrils, are formed [6,7]. However, the mechanisms through
which mutations lead to disease are not known. Multiplications of
the WT aSyn gene are also linked to PD, suggesting that a simple
increase in the levels of expression of the protein might be
sufficient to cause neurodegeneration [8]. Several in vitro studies
recapitulate this phenomenon, leading to aSyn deposition and
cytotoxicity [9–11].
The exact link between aSyn inclusions and cytotoxicity,
leading to disease onset and progression, is unclear but
accumulating evidence suggests nonfibrillar dimers and oligomers
of aSyn, intermediates for the formation of fibrillar inclusions and
Lewy bodies (LB), play an important role in neurodegeneration
[12–15]. Therefore, cellular processes that lead to either increased
formation of dimers and/or oligomers or, alternatively, decreased
clearance of these species, may be associated with aSyn-mediated
toxicity.
The direct visualization of protein complexes in living cells is a
challenging task, limited by the size of the complexes and the
resolution of the microscopes. While macroscopic inclusions,
including those containing aSyn, have been reported in several
models [16,17], the observation of smaller oligomeric and
prefibrillar species has only been done indirectly, through the
use of conformation-specific antibodies or biophysical techniques
such as atomic force microscopy (AFM) [18–20]. Moreover, the
effects of oligomeric and prefibrillar species on cells have not been
addressed directly, and the question remains as to what the nature
of the toxic species is.
In this study, we adapted a protein-fragment complementation
assay (PCA) approach to observe the initial aSyn-aSyn interactions
in living cells utilizing nonfluorescent fragments of GFP that can
reconstitute the fluorophore when brought together by interac-
tions between proteins covalently linked to each fragment [21,22].
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allows direct visualization of protein interactions in their normal
cellular environment and the determination of their subcellular
localization. Here, BiFC analysis allows the specific detection of a
subpopulation of aSyn that forms different types of oligomeric
species. Moreover, because complementation stabilizes the
complex, this approach allows one to selectively enrich oligomeric
species.
Materials and Methods
Construct Generation
aSyn BiFC constructs were generated by PCR using primers
59GGGCTTAAGGATGTATTCATGAAAGGAC39+59GGGCT-
CGAGTTAGGCTTCAGGTTCGTAGTC39 for aSyn, 59GGGG-
CTAGCGCCACCATGGTGAGCAAGGGCGAGG39 and 59GG-
GCTTAAGCTGCTTGTCGGCCATGATATAG39 for GN, and
59GGGCTTAAGGCCACCATGGATGTATTCATGAAAGGA-
C39+59GGGCTCGAGGGCTTCAGGTTCGTAGTC39and 59G-
GGCTCGAGAAGAACGGCATCAAGGTGAAC39+59GGTCT-
AGATTACTTGTACAGCTCGTCC39 for GC. PCR fragments
were digested, cloned into pcDNA3.1, and verified by DNA
sequencing.
aSyn BiFC constructs were subcloned from pcDNA3.1 into
pCMV-3Tag-8 (Invitrogen, Carlsbad, CA,USA). GN-link-aSyn
was subcloned as a SacI/XhoI fragment and aSyn-GC as a PmeI/
EcoRV fragment.
To make aSyn-hGLuc constructs, aSyn was subloned into the
NotI/ClaI sites of constructs (kindly provided by Dr. Steven
Michnick of the University of Montreal) containing optimized
fragments of hGLuc (1–93; 94–185) to generate syn-hGLuc(1) and
syn-hGLuc(2) fusion constructs.
Cell Culture and Transfections
Unless otherwise stated, human H4 neuroglioma cells were
maintained in OPTI-MEM medium supplemented with 10% fetal
bovine serum (both from Invitrogen) and incubated at 37uC. Cells
were plated 24 hours prior to transfection, growing to 80–90%
confluency prior to transfection. Transfection was performed using
Superfect (Qiagen, Chatsworth, CA, USA) according to the
manufacturer’s instructions.
For HEK (Human Embryonic Kidney) cells we used DMEM
(Invitrogen) supplemented with 10% FBS and for CHO (Chinese
Hamster Ovary) cells we used OPTI-MEM+10% FBS
BiFC-GFP Reconstitution Assay
For optimal fluorophore reconstitution, transiently transfected
cells were incubated overnight at 30uC [21,22] after an initial
,4 hour incubation at 37uC. 24 hours after transfection cells were
either observed using a Zeiss LSM510 confocal microscope or
harvested for preparing cell lysates.
Stable cells were also incubated overnight at 30uC prior to
harvesting or microscopy.
Gaussia luciferase protein-fragment complementation
assay
To establish the syn-hGLuc PCA, we subcloned asyn into the
NotI/ClaI sites of constructs containing optimized fragments of
hGLuc (1–93; 94–185) (kindly provided by Dr. Steven Michnick of
the University of Montreal). Subcloning generated syn-hGLuc(1)
and syn-hGLuc(2) fusion constructs which were transfected into
H4 cells in a 96-well plate format as described above. Twenty-four
hours after transfection, culture media was removed and replaced
with phenol-red free media. Luciferase activity from protein
complementation was measured in an automated plate reader at
480 nm following the injection of the cell permeable substrate,
coelenterazine (20 mM) (Prolume Ltd, Pinetop, AZ) and a signal
integration time of 2 seconds.
Live cell imaging
Cells were plated on poly-D-lysine coated coverslipped 35 mm
dishes (MatTek Cultureware, Ashland, MA, USA) and transfected
the following day. Cells were imaged 24 hours post-transfection
on a Zeiss LSM 510 confocal microscope system. Cells were
observed with a 256objective for distribution and quantification
analysis and with a 636 objective for subcellular localization
studies.
Quantification of Pixel Intensities
H4 cells were plated and imaged using Live cell imaging methods
discussed earlier. At the 24 hour timepoint cells were subjected to
confocal observation using a 488 nm Laser line and a 500–
550 nm emission band pass. Random fields consisting of 5–8 cells
per image were collected for each dish/condition at a 256/26
zoom setting. Prior to image collection, image and laser settings
that could affect image intensity and brightness were standardized
to a control or baseline dish. Adobe Photoshop was used to convert
the average GFP fluorescence of each cell to average pixel
intensity. Values were then averaged for each condition, and
statistical differences between an empty vector/baseline condition
and an experimental condition were calculated using a Student T-
test.
Native and denatured PAGE
At 24 hours post-transfection cells were washed with room
temperature PBS and then harvested.
Samples to be run under denaturing conditions were lysed with
lysis buffer containing Triton X-100 (0.1% Triton X-100, .15 M
NaCl, 50 mM Tris pH 7.5, protease inhibitor cocktail tablet 1
tablet/10 mL (Roche Diagnostics)), sheared by passing through a
27-gauge 1 mL syringe 4–6 times, and centrifuged for 1 min at
13,0006g.
For native gels, samples were lysed with detergent-free lysis
buffer (50 mM Tris/HCl pH 7.4, 175 mM NaCl, 5 mM EDTA
pH 8.0 and a protease inhibitor cocktail tablet (Roche)).
Protein concentration was determined using the BCA protein
assay and 20 mg of each lysate was loaded on the gel (Tris-glycine
gels, Invitrogen). For denaturing conditions, SDS-PAGE was
performed using Tris-Glycine SDS running buffer and SDS-
sample buffer (26, mixed with beta-mercaptoethanol at 1:50).
Native-PAGE was run with detergent-free Tris-Glycine running
buffer and 26 native sample buffer (Invitrogen). Proteins were
transferred to PVDF membrane (PerkinElmer) and processed for
immunoblotting. Membranes were blocked in either 5% milk in
TBS-T or Li-Cor blocking buffer (LI-COR,Lincoln, NE, USA) for
1 hour at room temperature. Membranes were then incubated
with primary antibodies (mouse anti-alpha-synuclein, 1:1000, BD
Transduction; Rabbit anti-GFP: polyclonal, 1:3000, Abcam) for
2–3 hours at room temperature or overnight at 4 C. After three 5–
10 min TBS-T washes, membranes were incubated at room
temperature for 1 hour with either IR-labeled secondary antibod-
ies (IR800 goat anti-mouse or anti-rabbit, 1:2000, Rockland
Immunochemicals, PA,USA), Alexa 680/700 goat anti-mouse and
goat anti-rabbit 1:2000,Molecular Probes, Eugene, OR,USA) or
HRP-conjugated secondary antibodies (1:2000). After three 5–
10 min TBS-T washes, immunoblots were analyzed using either
the Odyssey Infrared imaging system (Li-Cor, Lincoln, NE,USA)
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HealthCare, Buckinghamshire, UK).
Hoescht nuclear staining
Hoescht 33342 dye (10 mg/mL in solution, Molecular Probes/
Invitrogen) in OPTI-MEM+10%FBS was applied to cells at 1 mg/
mL and incubated for 30 minutes at room temperature. The
media was then removed and cells were imaged in PBS.
Cell culture, transfections, and immunocytochemistry
Human H4 neuroglioma cells (HTB-148 - ATCC, Manassas,
VA, USA) were maintained in OPTI-MEM (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal bovine
serum. H4 cells were passaged 24 h prior to transfection and
plated in 24-well plates. Cells were transfected with equimolar
ratios of plasmids using Superfect (Qiagen, Chatsworth, CA, USA)
according to the manufacturer’s instructions. After 24 hours, cells
were washed with PBS and fixed with 4% paraformaldehyde for
10 min at RT. After washing with PBS cells were permeabilized in
TBS containing 0.1% Triton X-100 for 20 min at RT. After
blocking in 1.5% normal goat serum containing TBS for 1 hour,
cells were incubated with primary antibody for 2 hours at RT or
overnight at 4uC (anti-aSyn – syn1, BD, or anti-GFP – Abcam)
followed by washing with PBS and secondary antibody incubation
for 1 hour (goat anti-mouse IgG-Alexa488, 1:300, Molecular
Probes, Eugene, OR, USA; goat anti-rabbit IgG-Cy3 1:500,
Rockland Immunochemicals, Gilbertsville, PA, USA). After a final
wash, slides were mounted with aqueous mounting solution (GVA,
Zymed, San Francisco, CA, USA) and subjected to fluorescence
microscopy.
aSyn toxicity assay
Toxicity was analyzed 24 hr after transfection by measuring the
release of adenylate kinase from damaged cells into the culture
medium using the ToxiLight
TM kit (Cambrex, Walkersville, MD)
according to the manufaturer’s protocol, using a luminescent
readout.
Fluorescent-activated cell sorting (FACS)
0.5–2.5610 cells per dish were plated and transfected in
100 mM dishes. 24 hours post transfection Trypsin was added to
each plate and neutralized with media (Opti-MemH+10% Fetal
Bovine Serum). The cell suspension was centrifuged, the
supernatant aspirated and the pellet reconstituted in phosphate
buffered saline (PBS). The resulting supernatant was filtered with
cell strainer caps into polypropylene tubes (both from BD
Biosciences). Fluorescence was measured on a FACSCanto (BD
Biosciences).
Results
To investigate whether aSyn forms dimers and/or oligomers in
living cells we adapted a fluorescent protein-fragment comple-
mentation assay (PCA) whereby we generated a variety of fusion
constructs containing non-fluorescent GFP fragments with or
without a poly-linker sequence (Table 1 and Fig. 1A). Protein
complementation only occurred when aSyn was fused to both
fragments of GFP, and was not observed when a GFP fragment
alone was expressed with GN-link-aSyn, indicating no spontane-
ous interaction occurred between the two GFP fragments (Table 1
and Fig. 1B–E). Complementation was stronger in cells expressing
GN-link-aSyn and aSyn-GC than in cells expressing aSyn-GN and
aSyn-GC, supporting an antiparallel interaction between two aSyn
molecules (Table 1 and Fig. 1A–F). GN-link-aSyn and aSyn-GC
constructs were used for all subsequent experiments. To ensure
aSyn oligomerization was not driven by the GFP moieties, we
explored a different PCA based on bioluminescence. This assay
works under the same principle as the fluorescent-protein PCA
except that it utilizes non-bioluminescent amino-terminal and
carboxy-terminal fragments of Gaussia princeps luciferase (hGLuc)
that can reconstitute when brought together by protein interac-
tions [23]. Bioluminescent-protein PCA also allows direct
monitoring of protein interactions in their normal cellular
environment. aSyn was subloned into constructs containing
optimized fragments of hGLuc (1–93; 94–185) to generate syn-
hGLuc(1) and syn-hGLuc(2) fusion constructs. Transient transfec-
tion of syn-hGLuc(1) and syn-hGLuc(2) resulted in luciferase
activity more than 5-fold above background (Fig. 1G). These data
are consistent with the GFP-based PCA and support the formation
of at least aSyn dimers.
Under the experimental conditions used no amyloid-like,
macroscopic intracellular aSyn inclusions were observed (Fig. 1
and immunucytochemistry data, not shown), suggesting that the
bimolecular interaction reflected by the successful GFP comple-
mentation represents pre-aggregate intermediate species as
previously suggested by FRET studies [24]; however, the fact
that complementation occurs with both N/C- and C/C-terminal
tags suggests that the assay can capture alternative oligomeric
species.
In principle, it would be possible that both aSyn dimers and
higher order oligomeric species would be detected using the BiFC
assay. To study the nature of the aSyn species visualized by the
BiFC assay, we employed non-denaturing (native) polyacrylamide
gel electrophoresis (PAGE). Immunoblotting with both aSyn and
GFP antibodies revealed a wide range of aSyn species in living
cells, from dimers to high molecular weight (MW) oligomeric
species (Fig. 1H). As expected, cells expressing either GN-link-
aSyn or aSyn-GC (or wild-type aSyn) also contained high MW
species under native conditions, however these oligomers were not
fluorescent and were unable to be observed using fluorescence
microscopy. Under denaturing conditions, discrete bands corre-
sponding to monomeric GN-link-aSyn and aSyn-GC were
observed (Fig. 1I).
It is known that GFP reconstitution via BiFC stabilizes the
protein-protein interactions of the proteins involved [22] which, in
the case of aSyn, is useful because it traps the oligomeric species in
a specific conformation. To assess the effect of complementation
Table 1. Constructs used in this study and complementation
results.
N-terminal fragment C-terminal fragment Fluorescence signal
GN GC -
GN-link-aSyn aSyn-link-GC -
GNaSyn aSyn-GC -
GN-link-aSyn aSyn-GC +++
GNaSyn aSyn-link-GC -
GN-link-aSyn GC -
GN aSyn-GC -
aSyn-GN aSyn-GC +
Complementation occurred only with the combinations shown in green. Co-
transfection of GN-link-aSyn with aSyn-GC resulted in the strongest fluorescent
signal (+++) indicating the most favorable interaction. All negative controls and
other combinations tested showed detectable fluorescent signal.
doi:10.1371/journal.pone.0001867.t001
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chase followed by SDS-PAGE. We found that oligomerization of
aSyn increased the half life of each of the individual fusions by
,40%. At 24 and 48 hours, the levels of GN-link-aSyn and aSyn-
GC are higher when the proteins are co-expressed (i.e. when the
oligomeric forms are stabilized by complementation) than when
they are expressed individually (Fig. 2A).
Given that the BIFC assay traps aSyn oligomeric species in a
specific conformation we next asked whether stabilized aSyn
oligomeric species increased overall aSyn cytotoxicity in H4 cells.
We found that, indeed, the levels of toxicity were increased in cells
expressing both GN-link-aSyn and aSyn-GC when compared to
cells expressing untagged aSyn or either of the GN-link-aSyn or
aSyn-GC constructs alone (Fig. 2B).
To determine whether different cellular environments, provided
by different cell lines, could support aSyn oligomerization, we co-
transfected neuronal and non-neuronal cell lines with the GN-link-
aSyn and aSyn-GC constructs and studied oligomer formation
Figure 1. aSyn forms dimers/oligomers in cells. A. Schematic of the constructs selected for the remainder of the study. B.–E. Confocal
microscopy showing the specificity of the complementation reaction driven by aSyn-aSyn interactions (Scale bar, 50 mm). F. FACS analysis of parallel
vs anti-parallel aSyn-aSyn interaction. G. aSyn-aSyn interactions were also monitored using a bioluminescent-protein PCA whereby non-
bioluminescent halves of G. princeps luciferase were fused to aSyn molecules. Cotransfection (S1+S2) results in a more than 5-fold increase in
luciferase activity compared to background single transfections (S1 or S2), indicative of at least dimer formation. H. Immunoblot of native PAGE of
cells transfected with GN-link-aSyn (1), aSyn-GC (2), and GN-link-aSyn+aSynGC (3) showing smears which are indicative of a wide range of oligomeric
species. I. Immunoblot of SDS-PAGE of the same cells as in G showing the levels of expression of GN-link-aSyn and aSynGC. Immunoblots were
probed with an antibody against EGFP (Abcam, Cambridge, USA).
doi:10.1371/journal.pone.0001867.g001
aSyn Oligomerization in Cells
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formed oligomers in all cell lines tested (Fig. 3), suggesting the
formation of oligomeric species is not the determining factor per se
for the specific vulnerability of certain cell types.
To assess the effect of familial PD mutations on aSyn
oligomerization, we generated GN-link-aSyn and aSyn-GC
constructs carrying the A53T, A30P and E46K mutations. Using
the BiFC assay we found that all three mutants formed dimers/
oligomers in H4 cells as assessed by GFP fluorophore reconstitu-
tion (Fig. 4A). While we were not able to detect significant
differences in the oligomerization pattern via fluorescent signal, we
identified different patterns in the biochemical nature of the
oligomers. The A30P mutant formed high MW species to a
greater degree than WT, A53T, or E46K (Fig. 4B). No statistically
significant differences in cytotoxicity were observed. We then
asked whether the oligomeric species formed by the WT aSyn and
each aSyn mutant were differentially distributed throughout the
cell. Using confocal microscopy we found all aSyn variants
displayed similar subcellular distributions, with oligomers being
found both in the cytosol and in the nucleus (Fig. 4C).
We and others have previously shown that overexpression of
Hsp70 reduces aSyn toxicity and aggregation in H4 cells and in
animal models of PD [25,26, #2463,27]. To investigate whether
the toxicity of aSyn dimers/oligomers could be reduced by
molecular chaperones, we co-transfected cells with GN-link-aSyn,
aSyn-GC and either empty vector or Hsp70. Cells co-expressing
Hsp70 displayed reduced cytotoxicity, demonstrating the protec-
tive effect of this protein towards the toxic effects exerted by aSyn
dimers/oligomers (Fig. 5A).
We next asked whether the rescue of cytotoxicity by Hsp70 was
associated with an effect on aSyn oligomerization. We found that
overexpression of Hsp70 reduced aSyn oligomerization in living
Figure 2. aSyn oligomers are stabilized by complementation and show increased cytotoxicity. A. The half lives of EGFP (1), aSyn-GC (2),
GN-link-aSyn (3), and GN-link-aSyn+aSynGC (4) were monitored via immunoblotting of H4 cells transfected with the different constructs and treated
with cycloheximide for the indicated period of time prior to cell harvesting. Immunoblots were probed with an antibody against EGFP (Abcam,
Cambridge, USA).B. Toxicity assay of cells transfected with EGFP (1), WT aSyn (2), GN-link-aSyn (3), aSyn-GC (4), and GN-link-aSyn+aSynGC (5) showing
that stabilization of aSyn oligomers leads to increased toxicity (*t-test, n=3, p,0.005).
doi:10.1371/journal.pone.0001867.g002
aSyn Oligomerization in Cells
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showing complementation can occur in the different cellular environments provided by each cell line (Scale bar, 50 mm).
doi:10.1371/journal.pone.0001867.g003
Figure 4. PD-associated aSyn mutations form oligomeric species. A. H4 cells were transfected with WT or mutant combinations of GN-link-
aSyn+aSynGC and analyzed via flow cytometry to quantify the fluorescence intensity. The fluorescence signal was identical for WT and mutant aSyn.
B. Immunoblots of native-PAGE showing oligomeric species formed by GN-link-aSyn+aSynGC (lane 1), WT aSyn (lanes 2 and 3), A53T (lane 4), A30P
(lane 5), and E46K (lane 6) and the corresponding expression levels (SDS-PAGE). C. Subcellular distribution, analyzed by confocal microscopy, of WT
and mutant aSyn oligomers in H4 cells showing cytoplasmic and nuclear localization (green). Hoescht staining highlight the nuclei in blue (Scale bar,
50 mm).
doi:10.1371/journal.pone.0001867.g004
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aSyn+aSynGC and either with an empty vector or with Hsp70. Cytotoxicity was reduced by Hsp70 (t-test, n=3, p,0.001). B. Confocal microscopy
analysis showing that overexpression of Hsp70 reduces aSyn oligomerization (Scale bar, 50 mm). C. Quantification of the pixel intensity of the same
cells as in B showing a statistically significant reduction in fluorescence in cells overexpressing Hsp70 (t-test, p,0.0001). D. Immunoblot of a native
PAGE of cells co-transfected with GN-link-aSyn+aSynGC and either an empty vector of with Hsp70 showing a strong reduction in high molecular
weight oligomeric species by Hsp70. E. Immunoblot of an SDS-PAGE of the same samples as in E showing Hsp70 overexpression does not lead to
decreased levels of GN-link-aSyn nor aSynGC. F. Quantification of the SDS-PAGE confirms that Hsp70 does not reduce the protein levels of GN-link-
aSyn nor aSyn-GC.
doi:10.1371/journal.pone.0001867.g005
aSyn Oligomerization in Cells
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in high MW species on a native PAGE (Fig. 5D). Importantly, the
reduction of aSyn oligomerization was not simply explained
through increased clearance of the monomeric forms, as the levels
of GN-link-aSyn and aSyn-GC were not reduced (Fig. 5E, F).
Thus Hsp70 selectively leads to clearance of aSyn in an oligomeric
conformation rather than a monomeric conformation.
Discussion
Protein misfolding and deposition are associated with several
brain disorders, including Alzheimer’s disease (AD) and PD, the
two most common neurodegenerative diseases. Fibrillar, macro-
scopic inclusions made up primarily of aSyn, called LBs, are found
in the brains of patients with PD and other diseases collectively
known as synucleinopathies. The intermediary species that
precede amyloid formation are thought to be more toxic than
the inclusions themselves, but studying these presumed toxic
species in cells has been difficult. In vitro, purified aSyn forms
oligomeric species prior to the formation of larger structures with
amyloid-like properties [7,18,19,28,29], but in living cells it has
not been possible to study the range of intermediary species that
fall between monomeric and aggregated forms of the protein. This
has obscured the understanding of the molecular mechanisms
leading to neurodegeneration and the development of efficacious
therapeutics directed at eliminating the source of toxicity.
Recently, novel protocols enabled the generation of aSyn
oligomers from purified proteins, and their effects on cells
suggested heterogeneous populations lead to cell death [30]. The
present study takes advantage of a novel assay that enables the
direct visualization of protein-protein interactions in the context of
a living cell, using GFP as a reporter [22]. We sought to
investigate, in living cells, the initial interactions that lead to the
formation of intermediary aSyn oligomeric/pre-aggregated spe-
cies. We monitored aSyn dimerization by fusing non-fluorescent
fragments of GFP (amino acids 1–155 or 156–238) to the N- and
C-termini of aSyn molecules and observed reconstitution of the
functional GFP fluorophore only in conditions where the two
fragments were brought together by aSyn-aSyn interactions. aSyn
dimers formed throughout the cell, including in the nucleus,
suggesting different subcellular environments can offer a produc-
tive environment for dimerization. Importantly, aSyn has recently
been shown to occur in the nucleus and to bind directly to histones
[31]. Our data are consistent with this finding and demonstrate
that aSyn dimers and oligomers are also present in the nucleus.
The BiFC assay is known to lead to the stabilization of the
interaction between the proteins of interest due to the reconsti-
tution of the GFP moiety [22]. This property of the assay allowed us
to address a central question in the field which is whether pre-
aggregated species (dimers, trimers, oligomers, etc) are more or less
toxic than WT aSyn [9,16,17]. Importantly, we found that
stabilizing aSyn oligomeric species led to a statistically significant
increase in cytotoxicity (,20%). Using native PAGE we could
detect aSyn oligomeric species for all the constructs tested, including
WT aSyn, as expected, but when aSyn oligomers were stabilized by
complementation the half lives of the oligomeric species were
increased, along with a concomitant increase in cytotoxicity.
Importantly, the converse experiment also implicates oligomeric
forms of aSyn in toxicity. Overexpression of the chaperone Hsp70
selectively impacts high MW species (rather than monomeric forms
of aSyn) and has a clear cytoprotective effect.
The possibility exists that the fusion of GFP fragments to aSyn
may influence its behavior, however in similar experiments
performed with fragments of humanized Gaussia luciferase [23]
fused to aSyn, the data presented herein were successfully
replicated, which suggests that GFP is not responsible for driving
the observed interactions. An important aspect of the BiFC assay is
that oligomeric forms of aSyn can be directly visualized in living
cells, providing insight into subcellular localization. Interestingly, in
this case, the aSyn oligomers are strongly visualized in the nucleus.
Overall, our data demonstrate that the formation of dimeric and
oligomeric aSyn species, both of which are thought to precede the
formation of larger intracellular inclusions, are central steps
towards cytotoxicity which can be targeted through the activity of
molecular chaperones, such as Hsp70. Further studies will be
necessary to investigate the formation of aSyn dimers and
oligomers in animal models and to assess their toxicity.
Nevertheless, through the use of this novel powerful assay, our
work opens new avenues for investigating the precise nature of the
toxic aSyn species and for using oligomeric species as a target for
therapeutic intervention in PD and other synucleinopathies.
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